WO2009011912A8 - A composition for treating hiv comprising virus-like particles - Google Patents

A composition for treating hiv comprising virus-like particles Download PDF

Info

Publication number
WO2009011912A8
WO2009011912A8 PCT/US2008/008799 US2008008799W WO2009011912A8 WO 2009011912 A8 WO2009011912 A8 WO 2009011912A8 US 2008008799 W US2008008799 W US 2008008799W WO 2009011912 A8 WO2009011912 A8 WO 2009011912A8
Authority
WO
WIPO (PCT)
Prior art keywords
virus
particles
composition
treating hiv
mutations
Prior art date
Application number
PCT/US2008/008799
Other languages
French (fr)
Other versions
WO2009011912A1 (en
Inventor
Hsu-Tso Ho
Pin-Fang Lin
Li Fan
Brian Vincent Mcauliffe
Original Assignee
Bristol Myers Squibb Co
Hsu-Tso Ho
Pin-Fang Lin
Li Fan
Brian Vincent Mcauliffe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Hsu-Tso Ho, Pin-Fang Lin, Li Fan, Brian Vincent Mcauliffe filed Critical Bristol Myers Squibb Co
Publication of WO2009011912A1 publication Critical patent/WO2009011912A1/en
Publication of WO2009011912A8 publication Critical patent/WO2009011912A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides an HTV VLP having one or more mutations in (gp160). The HIV VLP may be administered to a patient alone, in combination with one or more additional VLPs having one or more mutations in gp (160), in combination with an attachment inhibitor or in combination with an attachment inhibitor and one or more additional VLPs having one or more mutations in gp (160).
PCT/US2008/008799 2007-07-18 2008-07-18 A composition for treating hiv comprising virus-like particles WO2009011912A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95993607P 2007-07-18 2007-07-18
US60/959,936 2007-07-18

Publications (2)

Publication Number Publication Date
WO2009011912A1 WO2009011912A1 (en) 2009-01-22
WO2009011912A8 true WO2009011912A8 (en) 2009-07-23

Family

ID=39930596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/008799 WO2009011912A1 (en) 2007-07-18 2008-07-18 A composition for treating hiv comprising virus-like particles

Country Status (1)

Country Link
WO (1) WO2009011912A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178079A1 (en) 2018-03-12 2019-09-19 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676071B1 (en) * 1991-05-02 1994-11-18 Transgene Sa NEW NON-CLeavABLE, SOLUBLE, HYBRID-FORMING GP160 VARIANT.
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
WO2007039458A2 (en) * 2005-09-21 2007-04-12 Cytos Biotechnology Ag Hiv peptide conjugates and uses thereof

Also Published As

Publication number Publication date
WO2009011912A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
WO2010062396A3 (en) Virus like particle compositions and methods of use
WO2006076003A3 (en) Vaccinia virus strains
WO2008127364A3 (en) Antiviral compounds and use thereof
NZ603386A (en) Pharmaceutical compositions and administrations thereof
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2007146426A3 (en) Nanoshells for drug delivery
EP2476461A3 (en) Formulations For Cancer Treatment
WO2007077561A3 (en) Compositions and methods for enhancing in-vivo uptake of pharmaceutical agents
WO2008045238A3 (en) Stabilized therapeutic small helical antiviral peptides
WO2008100292A8 (en) Modified vaccinia virus strains for use in diagnostic and therapeutic methods
TW200833684A (en) 5,6-ring annulated indole derivatives and methods of use thereof
WO2007149406A3 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
WO2007081974A3 (en) Viral hepatitis treatment
WO2013057570A3 (en) Acrylic polymer formulations
WO2007125105A3 (en) Benzamide glucokinase activators
MX2010005107A (en) Silibinin component for the treatment of hepatitis.
WO2007130616A3 (en) Polyamides for treating human papilloma virus
WO2012016139A3 (en) Sirna compositions and methods for treatment of hpv and other infections
MX2009009743A (en) Powders for reconstitution.
ZA201004337B (en) Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing the same
WO2009078977A9 (en) Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins
WO2008033500A3 (en) Carbohydrate-based vaccines for hiv
HK1120417A1 (en) Stable nanoparticle formulations
WO2008059041A3 (en) Complementation of factor xi deficiency by factor v mutants
WO2011087738A3 (en) 1,4-substituted piperazine derivatives and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08780257

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08780257

Country of ref document: EP

Kind code of ref document: A1